dpp-4 inhibitor with glp-1 receptor agonist combination not recommended ada agonists or inhibitors: How to guide the clinician? What drug combination with DPP-4

Acknowledgments This project was initiated by the Obesity Management Collaboration-UK (OMC-UK), which is a professional support network of healthcare professionals with an interest in obesity treatment

95% CI 17.86, 0.52), metformin (WMD: 9.14

We are running a global experiment at scale, with no long-term map

Among the GLP-1 RAs and a dual GLP-1/GIP RA, exenatide has the most developed pharmacokinetic model (9 of 30), 61,177184 followed by semaglutide (8 of 30), 68,162,182,185189 liraglutide and dulaglutide (each 5 of 30), 156,177,182,189194 and tirzepatide (3 of 30)

Furthermore, Semaglutide GLP-1 is not just a weight loss medication

GLP-1 influences food and drug reward